๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects

โœ Scribed by U. Voderholzer; D. Riemann; M. Hornyak; J. Backhaus; B. Feige; M. Berger; F. Hohagen

Publisher
Springer-Verlag
Year
2001
Tongue
English
Weight
287 KB
Volume
251
Category
Article
ISSN
1433-8491

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A double-blind, placebo-controlled study
A double-blind, placebo-controlled study of the effects of eptastigmine on scopolamine-induced cognitive deficits in healthy male subjects
โœ C. R. Lines; J. H. Ambrose; A. Heald; M. Traub ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 612 KB

This double-blind, placebo-controlled, crossover study examined the effects of two single doses of eptastigmine, a novel cholinesterase inhibitor, on scopolamine-induced cognitive deficits in 24 healthy male volunteers. Each subject received the following treatment sequences, separated by at least 1

A phase 2, randomized, double-blind, pla
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis
โœ Vlad Ratziu; Muhammad Y. Sheikh; Arun J. Sanyal; Joseph K. Lim; Hari Conjeevaram ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 356 KB

In nonalcoholic steatohepatitis (NASH), the extent of hepatocyte apoptosis correlates with disease severity. Reducing hepatocyte apoptosis with the selective caspase inhibitor GS-9450 has a potential for altering the course of the liver disease. In this phase 2, double-blind study, 124 subjects with